L-670596 

L-670596 is an orally active and selective thrombsxane A2 receptor/prostaglandin receptor antagonist. L-670596 inhibits arachidonic acid (HY-109590) and U-44069 induced bronchoconstriction in the guinea pig. L-670596 also inhibits the aggregation of human platelet rich plasma induced by U-44069^[1][2].

L-670596 inhibits the aggregation of human platelet rich plasma induced by U-44069^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

L-670596 (0.03mg/kg ; i.v.; single) inhibits arachidonic acid and U-44069 induced bronchoconstriction in the guinea pig^[1].
L-670596 (2 mg/kg; i.v.; single) inhibits platelet aggregation to collagen in pigs^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

433.47

C₂₂H₂₁F₂NO₄S

121083-05-4

O=C(O)CC1C(N(CC2=CC=C(S(=O)(C)=O)C=C2)C3=C4C=C(F)C=C3F)=C4CCC1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ford-Hutchinson AW, et al. The pharmacology of L-670,596, a potent and selective thromboxane/prostaglandin endoperoxide receptor antagonist. Can J Physiol Pharmacol. 1989 Sep;67(9):989-93.  [Content Brief]

  [2]. Nuttall GA, et al. Protamine-heparin-induced pulmonary hypertension in pigs: effects of treatment with a thromboxane receptor antagonist on hemodynamics and coagulation. Anesthesiology. 1991 Jan;74(1):138-45.  [Content Brief]